Hey Reg,
Thanks mate.
I was being a bit comical there really.
Not sure why some posters on this forum think that something that works well in paediatric trials would think that it would not also work in adults generally, we are all
still human right.
Especially when results from Rem-l have proven to work well in adults from recent compassionate use.
It sounds like some posters on here don’t want to look at all the facts in MSB products and only cherry pick from very old data points.
I wonder why they would do that
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-377
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.008(0.59%) |
Mkt cap ! $1.478B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.29 | $420.8K | 325.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 17606 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 12045 | 8 |
View Market Depth
| Last trade - 10.59am 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |